GLP-1glp-1atrial-fibrillationtype-2-diabetescohort-study

Cohort study links GLP-1 agonists to thromboembolic risk in atrial fibrillation

The propensity score-matched analysis in Diabetes, Obesity & Metabolism focuses on patients with type 2 diabetes who also have atrial fibrillation or flutter.

By Maren Holt · Senior Reporter, GLP-1

Oct 11 20:00 ETSource: Diabetes, obesity & metabolism

The wire

01Researchers report a propensity score-matched cohort study of GLP-1 receptor agonist use and thromboembolic events in patients with type 2 diabetes and atrial fibrillation or flutter.
02Prescribers managing incretin therapy in anticoagulated or arrhythmia patients have asked for comparative safety data in this specific subgroup.
03Observational matched cohorts cannot establish causation and remain open to residual confounding; the full effect estimates and cohort size sit in the published paper.

From the source

GLP-1 Receptor Agonists and Thromboembolic Risk in Patients With Atrial Fibrillation or Flutter and Type 2 Diabetes: A Propensity Score-Matched Cohort Study
Diabetes, obesity & metabolism · 2026 Oct 12 · Lo SW, Liao TE, Ramachandran SP et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42864268/